✦ LIBER ✦

P724 VIROLOGICAL RESPONSE IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION RECEIVING FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IS UNAFFECTED BY RIBAVIRIN DOSE REDUCTION

✍ Scribed by Asselah, T.; Jensen, D.M.; Foster, G.R.; Sulkowski, M.S.; Ouzan, D.; Morano, L.; Buynak, R.; Agarwal, K.; Hassanein, T.; Forton, D.; Cho, M.; Genné, D.; Kaita, K.; Maieron, A.; Preotescu, L.; Sarrazin, C.; Zehnter, E.; Streinu-Cercel, A.; Stern, J.O.; Datsenko, Y.; Drulak, M.; Voss, F.; Quinson, A.-M.; Ferenci, P.

Book ID: 122250056
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 68 KB
Volume: 60
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(14)60886-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Su1053 Virological Response in Treatment

Su1053 Virological Response in Treatment-Naïve Patients With Chronic HCV Genotype-1 Infection Receiving Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin Is Unaffected by Ribavirin Dose Reduction

✍ Asselah, Tarik; Jensen, Donald M.; Foster, Graham; Sulkowski, Mark; Ouzan, Denis 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 1018 KB

P721 INTERFERON-STIMULATED GENE EXPRESSI

P721 INTERFERON-STIMULATED GENE EXPRESSION IS ASSOCIATED WITH TREATMENT RESPONSE TO FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION

✍ Datsenko, Y.; Baum, P.; Schirmbeck, R.; Stern, J.O.; Sha, N.; Steinmann, G.G. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 81 KB

Su1025 Interferon-Stimulated Gene Expres

Su1025 Interferon-Stimulated Gene Expression Is Associated With Treatment Response to Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin in Patients With Chronic HCV Genotype-1 Infection

✍ Datsenko, Yakov; Baum, Patrick; Schirmbeck, Reinhold; Stern, Jerry O.; Sha, Nans 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 563 KB

P1129 EFFECT OF HCV GENOTYPE-1 SUBTYPE O

P1129 EFFECT OF HCV GENOTYPE-1 SUBTYPE ON RESPONSE TO FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: POOLED DATA FROM PHASE III TRIALS

✍ Jacobson, I.M.; Jensen, D.M.; Dieterich, D.; Sarrazin, C.; Foster, G.R.; Yoshida 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 67 KB

1416 FALDAPREVIR PLUS PEGYLATED INTERFER

1416 FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAÏVE PATIENTS: FINAL RESULTS FROM STARTVERSO1, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL

✍ Ferenci, P.; Asselah, T.; Foster, G.R.; Zeuzem, S.; Sarrazin, C.; Moreno, C.; Ou 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 73 KB

2009 SAFETY AND ANTIVIRAL ACTIVITY OF AN

2009 SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS

✍ Lawitz, E.; Rodriquez-Torres, M.; Rustgi, V.K.; Hassanein, T.; Rahimy, M.H.; Cro 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 51 KB